state-of-the-art translational research
Our Research & Innovation scientists carry out intensive research to discover novel EEG biomarkers of brain disorders, which will become available for further compound testing.
Check out our process below and view our latest progresses.
Willing to collaborate on a project?
Join our Open Innovation Program.
1
CLINICAL STATE-OF-THE-ART
Intensive review of clinical litterature to find out which EEG signatures have been identified in human patients with brain diseases.
Exchanges with physicians on their clinical practice and review of protocols, pharmacology and data.
2
CLINICALLY-RELEVANT MODEL
Identification and selection of appropriate animal model from litterature, collaborations. Animal modeling.
3
MODEL PHENOTYPING
Rodent model Phenotyping by EEG, LFP, ecoG: It is possible to phenotype a model you find relevant for your research, either from your lab or from a third-party provider.
4
Oscillatory signatures identification
Does the brain of the model express EEG signatures that are specific to the disease and similar to patterns found in human patients?
5
PHARMACOLOGICAL CHALLENGE
Validation of the oscillattory signature's robustness with a pharmacology of reference (if it exists). In case of success, the oscillatory signature can be used as a surrogate biomarker of the disease.
6
BIOMARKER VALIDATION
Additional battery of tests are carried out to confirm the robustness of the biomarker. That include increase of animal cohort size, more pharmacological challenges and deeper statistical analysis.
1
CLINICAL STATE-OF-THE-ART
2
CLINICALLY-RELEVANT MODEL
3
MODEL PHENOTYPING
4
Oscillatory signatures identification
5
PHARMACOLOGICAL CHALLENGE
6
BIOMARKER VALIDATION
INNOVATING RESTLESSLY
TO PUSH THE BOUNDARIES OF NEUROSCIENCES
Let's talk about your next project
Bâtiment SYNERGY
ZAC ISIPARC
38330 Saint Ismier – France
OPEN INNOVATION
CAPABILITIES
SYNAPCELL 2022 © – All Rights Reserved